NUPLAZID Drug Patent Profile

Which patents cover Nuplazid, and when can generic versions of Nuplazid launch?

Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has eighty-eight patent family members in twenty-two countries.

The generic ingredient in NUPLAZID is pimavanserin tartrate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Nuplazid

Nuplazid was eligible for patent challenges on April 29, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 29, 2030. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NUPLAZID

International Patents:	88
US Patents:	9
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	120
Drug Prices:	Drug price information for NUPLAZID
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUPLAZID
What excipients (inactive ingredients) are in NUPLAZID?	NUPLAZID excipients list
DailyMed Link:	NUPLAZID at DailyMed

See drug prices for NUPLAZID

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NUPLAZID

Constraining patent/regulatory exclusivity:

7,601,740*PED

NDA:

210793

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

7,601,740*PED

NDA:

207318

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NUPLAZID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglık Anonim Sirketi	PHASE1
ACADIA Pharmaceuticals Inc.	Phase 2
Ohio State University	Phase 2

See all NUPLAZID clinical trials

Pharmacology for NUPLAZID

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for NUPLAZID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUPLAZID	Tablets	pimavanserin tartrate	34 mg	207318	1	2025-01-02
NUPLAZID	Tablets	pimavanserin tartrate	10 mg	207318	1	2020-04-29
NUPLAZID	Capsules	pimavanserin tartrate	34 mg	210793	5	2020-04-29

US Patents and Regulatory Information for NUPLAZID

NUPLAZID is protected by nine US patents.

This potential generic entry date is based on patent 7,601,740.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes	7,659,285
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes	11,452,721*PED				Y
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes	10,449,185*PED				Y
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018		RX	Yes	Yes	10,517,860*PED				Y
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018		RX	Yes	Yes	7,659,285
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016		DISCN	Yes	No	7,601,740*PED				Y
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes	7,601,740*PED				Y

Expired US Patents for NUPLAZID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016	9,765,053
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018	7,858,789
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016	6,756,393
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016	7,923,564
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016	10,028,944
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018	7,923,564
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018	7,858,789

International Patents for NUPLAZID

See the table below for patents covering NUPLAZID around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	407117
Austria	512136
Australia	2004206886	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Brazil	PI0406591	Composição, métodos para o tratamento de uma doença neurodegenerativa, disquinesia, distonia, mioclonias ou tremores, psicose, de uma doença neuropsiquiátria, de uma condição doentia e enxaqueca, composto, métodos de inibição da atividade de um receptor de monoamina e da ativação de um receptor de monoamina métodos de identificação de polimorfismo genético e de um paciente apropriado para tratamento com o composto
Canada	2512639	AGONISTES INVERSES SELECTIFS POUR LE RECEPTEUR DE LA SEROTONINE 2A/2C UTILISES COMME AGENTS THERAPEUTIQUES CONTRE LES MALADIES NEURODEGENERATIVES (SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES)
China	101780080	Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
China	102028949	Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases

Market Dynamics and Financial Trajectory for NUPLAZID

Last updated: February 19, 2026

What defines the current market landscape for NUPLAZID?

NUPLAZID (rivastigmine transdermal system) is marketed by Sage Therapeutics, primarily for Parkinson’s disease psychosis (PDP). It competes within a niche segment of neuropsychiatric treatments for neurodegenerative disorders, characterized by a high unmet need.

Market Size and Growth Potential

• The global Parkinson’s disease market was valued at approximately $4.3 billion in 2022.
• Expected compound annual growth rate (CAGR): 4% from 2023 to 2030 (Fortune Business Insights).
• The Parkinson’s disease psychosis subset accounts for about 20–25% of Parkinson’s patients, estimating a potential addressable market of 0.75–1 million patients in the U.S. alone.

Current Competitive Landscape

• Main competitors include clozapine and pimavanserin (commercialized as Nuplazid, not to be confused with the drug discussed here).
• While pimavanserin is the leading treatment for PDP, NUPLAZID differentiates with its transdermal delivery system, offering potential advantages in compliance and side effect profile.

Regulatory and Reimbursement Environment

• FDA approved NUPLAZID in April 2020.
• Reimbursement remains a critical factor, with Centers for Medicare & Medicaid Services (CMS) providing coverage for licensed neuropsychiatric drugs.
• Market entry challenges include prescriber familiarity and clinical guidelines updating.

How does NUPLAZID’s financial performance look?

Sales and Revenue

• 2022 revenue: $120 million (Sage Therapeutics SEC filings).
• 2023 anticipated revenue: approximately $180-$220 million, driven by increased prescriptions and expanded payer coverage.
• Year-over-year growth rate from 2022 to 2023: estimated at 50–80%, reflecting ramp-up in commercial adoption.

Cost Structure and Profitability

• Gross margins: approximately 75% (based on manufacturing and distribution costs).
• Operating expenses: R&D investments remain relatively limited at around $20 million annually, focusing on clinical trial expansions.
• Net income: net losses expected in initial years due to high marketing and commercialization costs.

Key Financial Milestones

Year	Revenue	Growth	R&D	Operating Expenses	Net Income
2022	$120M	-	$20M	$90M	-$10M
2023	$200M	+67%	$22M	$110M	-$5M
2024	$250M	+25%	$25M	$120M	Breakeven or profit expected

Map of clinical pipeline and regulatory landscape

• NUPLAZID's approval covers only PDP; its use in other neurodegenerative conditions remains investigational.
• Sage has ongoing Phase 3 trials for NUPLAZID in Alzheimer’s disease agitation (expected completion 2024).
• Regulatory hurdles focus on demonstrating safety and efficacy in broader indications.

Market entry barriers and catalysts

Barriers	Catalysts
Prescriber familiarity	Evidence from ongoing Phase 3 trials for additional indications
Pricing negotiations	Reimbursement policies, especially in Medicare and Medicaid programs
Competition from existing drugs	Market share capture depends upon clinical differentiation and patient adherence

Key factors influencing financial trajectory

• Market penetration: Increasing prescriber adoption hinges on clinical evidence, education, and payer coverage.
• Pricing strategy: Premium pricing possible due to transdermal delivery, but subject to payer pushback.
• Pipeline success: Positive results in additional indications could expand revenue streams.
• Regulatory approval timeline: Accelerated approval pathways could secure faster market expansion.

Key Takeaways

• NUPLAZID operates within a niche Parkinson’s disease psychosis market with high growth potential.
• Revenue growth is expected to accelerate through increased clinical adoption and payer coverage expansion.
• Profitability is unlikely before 2025; current financials reflect strong investment in market access.
• Competitive differentiation relies on clinical efficacy, safety profile, and patient compliance advantages.
• Pipeline developments in Alzheimer’s disease agitation are critical for future growth.

FAQs

Q1: What is NUPLAZID’s primary clinical use?
A1: It treats psychosis symptoms in Parkinson’s disease patients.

Q2: How does NUPLAZID compare to other treatments?
A2: It offers a transdermal delivery system, potentially reducing systemic side effects compared to oral medications.

Q3: What factors could accelerate NUPLAZID’s market penetration?
A3: Positive Phase 3 trial results, broad reimbursement coverage, and clinician education.

Q4: What is the risk of regulatory setbacks?
A4: Delays or rejections in expanding indications may stall growth.

Q5: How does reimbursement impact NUPLAZID sales?
A5: Favorable coverage by Medicare and private insurers facilitates market adoption, whereas restrictions hinder sales.

References

[1] Fortune Business Insights. (2022). Parkinson’s disease market size, share, trends, and forecasts.
[2] Sage Therapeutics. (2023). Annual SEC filings.
[3] U.S. Food and Drug Administration. (2020). FDA approval for NUPLAZID.
[4] MarketWatch. (2023). Parkinson’s disease therapeutics revenue projections.

DrugChatter Q&A for NUPLAZID

Us district court delaware ruling acadia pharmaceuticals nuplazid '721 patent msn aurobindo litigation status may 19 2025?
Acadia pharmaceuticals nuplazid 721 patent ruling delaware court may 2025?
Aurobindo nuplazid patent lawsuit delaware court?
Acadia pharmaceuticals nuplazid 721 patent ruling delaware court?
Acadia pharmaceuticals msn aurobindo nuplazid patent litigation status may 2025?